X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare TTK HEALTHCARE with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TTK HEALTHCARE vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TTK HEALTHCARE BIOCON LTD TTK HEALTHCARE/
BIOCON LTD
 
P/E (TTM) x 29.1 36.6 79.4% View Chart
P/BV x 5.4 4.9 110.1% View Chart
Dividend Yield % 0.5 1.5 35.7%  

Financials

 TTK HEALTHCARE   BIOCON LTD
EQUITY SHARE DATA
    TTK HEALTHCARE
Mar-14
BIOCON LTD
Mar-16
TTK HEALTHCARE/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs663496 133.8%   
Low Rs399397 100.6%   
Sales per share (Unadj.) Rs535.6174.3 307.4%  
Earnings per share (Unadj.) Rs15.944.8 35.6%  
Cash flow per share (Unadj.) Rs20.056.9 35.2%  
Dividends per share (Unadj.) Rs4.005.00 80.0%  
Dividend yield (eoy) %0.81.1 67.2%  
Book value per share (Unadj.) Rs137.6202.8 67.9%  
Shares outstanding (eoy) m7.77200.00 3.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.02.6 38.7%   
Avg P/E ratio x33.310.0 334.6%  
P/CF ratio (eoy) x26.57.8 338.5%  
Price / Book Value ratio x3.92.2 175.5%  
Dividend payout %25.111.2 224.8%   
Avg Mkt Cap Rs m4,12789,220 4.6%   
No. of employees `0001.74.4 38.7%   
Total wages/salary Rs m6076,363 9.5%   
Avg. sales/employee Rs Th2,436.77,894.5 30.9%   
Avg. wages/employee Rs Th355.21,441.2 24.6%   
Avg. net profit/employee Rs Th72.52,029.7 3.6%   
INCOME DATA
Net Sales Rs m4,16234,854 11.9%  
Other income Rs m61845 7.2%   
Total revenues Rs m4,22335,699 11.8%   
Gross profit Rs m1978,200 2.4%  
Depreciation Rs m322,423 1.3%   
Interest Rs m30102 29.3%   
Profit before tax Rs m1976,520 3.0%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m732,569 2.8%   
Profit after tax Rs m1248,961 1.4%  
Gross profit margin %4.723.5 20.1%  
Effective tax rate %37.039.4 93.9%   
Net profit margin %3.025.7 11.6%  
BALANCE SHEET DATA
Current assets Rs m1,62939,932 4.1%   
Current liabilities Rs m1,05816,276 6.5%   
Net working cap to sales %13.767.9 20.2%  
Current ratio x1.52.5 62.8%  
Inventory Days Days3054 55.6%  
Debtors Days Days3486 39.0%  
Net fixed assets Rs m55639,101 1.4%   
Share capital Rs m781,000 7.8%   
"Free" reserves Rs m87838,591 2.3%   
Net worth Rs m1,06940,556 2.6%   
Long term debt Rs m15920,724 0.8%   
Total assets Rs m2,39984,816 2.8%  
Interest coverage x7.664.9 11.7%   
Debt to equity ratio x0.10.5 29.0%  
Sales to assets ratio x1.70.4 422.1%   
Return on assets %6.410.7 60.0%  
Return on equity %11.622.1 52.4%  
Return on capital %18.519.0 97.2%  
Exports to sales %0.830.7 2.6%   
Imports to sales %1.420.4 6.9%   
Exports (fob) Rs m3310,717 0.3%   
Imports (cif) Rs m587,105 0.8%   
Fx inflow Rs m3311,789 0.3%   
Fx outflow Rs m638,393 0.8%   
Net fx Rs m-303,396 -0.9%   
CASH FLOW
From Operations Rs m1275,264 2.4%  
From Investments Rs m-146-9,540 1.5%  
From Financial Activity Rs m2210,867 0.2%  
Net Cashflow Rs m36,591 0.0%  

Share Holding

Indian Promoters % 65.4 40.4 161.9%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 3.7 8.4 44.0%  
FIIs % 5.2 10.7 48.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.8 19.9 129.6%  
Shareholders   12,723 109,995 11.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TTK HEALTHCARE With:   DISHMAN PHARMA  CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare TTK HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TTK HEALTHCARE SHARE PRICE


Aug 18, 2017 (Close)

TRACK TTK HEALTHCARE

  • Track your investment in TTK HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TTK HEALTHCARE

TTK HEALTHCARE - AJANTA PHARMA COMPARISON

COMPARE TTK HEALTHCARE WITH

MARKET STATS